By a GenomeWeb Staff Reporter

NEW YORK (GenomeWeb News) – Quest Diagnostics today said that it has commenced its tender offer to acquire Celera for $8 per share.

The offer is being made through Quest's wholly owned subsidiary, Spark Acquisition Corp., and will expire on April 25 at 5:00 pm New York City time. The offer is subject to customary conditions, including the tender of a majority of Celera's outstanding shares and certain regulatory approvals.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.